{"id":7588,"date":"2025-12-07T08:00:52","date_gmt":"2025-12-07T07:00:52","guid":{"rendered":"https:\/\/beigen.vipdev.lndo.site\/us\/?post_type=congress-resource&#038;p=7588"},"modified":"2025-12-07T14:00:18","modified_gmt":"2025-12-07T13:00:18","slug":"phase-1-1b-bgb-11417-101-study-of-sonrotoclax-plus-zanubrutinib-in-tn-cll-sll_umrd","status":"publish","type":"congress-resource","link":"https:\/\/beonemedaffairs.com\/us\/congress-resource\/7588\/phase-1-1b-bgb-11417-101-study-of-sonrotoclax-plus-zanubrutinib-in-tn-cll-sll_umrd\/","title":{"rendered":"Frontline treatment of sonrotoclax (BGB-11417) and zanubrutinib for chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) demonstrates high undetectable minimal residual disease (uMRD) rates with favorable tolerability: Updated data from BGB-11417-101, an ongoing phase 1\/1b study"},"content":{"rendered":"","protected":false},"template":"","post-tag":[760,704,614,630,827,673,628,594,781,877,876,595,537,542],"class_list":["post-7588","congress-resource","type-congress-resource","status-publish","hentry","post-tag-american-society-of-hematology","post-tag-ash","post-tag-bcl-2-inhibitor","post-tag-bcl2i","post-tag-bgb-11417","post-tag-btk-inhibitor","post-tag-btki","post-tag-chronic-lymphocytic-leukemia","post-tag-cll-sll","post-tag-minimal-residual-disease","post-tag-mrd","post-tag-small-lymphocytic-lymphoma","post-tag-sonrotoclax","post-tag-zanubrutinib","congress_resource_type-poster","content_type-reading","disease_state-chronic-lymphocytic-leukemia","disease_state-small-lymphocytic-lymphoma","molecule-bgb-11417","molecule-sonrotoclax","molecule-zanubrutinib"],"acf":{"congress_resource_url_override":"ash-2025","congress":6819,"category":245,"prioritization":0,"key_data_presentation":true,"key_data_presentation_only":false,"key_data_presentation_prioritization":20,"tags":[704,760,781,594,595,827,537,542,630,614,628,673,876,877],"visible_tags":[704,781,827,537,542],"content-type":246,"summary":"","text_app":"&nbsp;\r\n\r\nThis study assessed sonrotoclax plus zanubrutinib in untreated chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) patients. Among 137 patients, the investigational combination was generally well tolerated, with no treatment-related deaths reported. The most common any-grade treatment-emergent AEs (TEAEs) were neutropenia, COVID-19, contusion, and diarrhea. No clinical or laboratory tumor lysis syndrome (TLS) occurred, and only 9 patients discontinued combination treatment due to TEAEs. All patients responded to therapy, and nearly all achieved deep remission (undetectable disease in the blood). These deep responses occurred early and were maintained over time, including in patients with high-risk genetic features. The results support further research into this combination as a frontline therapy for CLL\/SLL.\r\n\r\n<em>The contents of the presentations above are designed for educational and scientific exchange purposes and are not promotional. They may contain information on investigational products or investigational uses of approved products. No conclusions regarding safety and\/or efficacy for such investigational products or uses may be made.<\/em>","text":"&nbsp;\r\n\r\nThis study assessed sonrotoclax plus zanubrutinib in untreated chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) patients. Among 137 patients, the investigational combination was generally well tolerated, with no treatment-related deaths reported. The most common any-grade treatment-emergent AEs (TEAEs) were neutropenia, COVID-19, contusion, and diarrhea. No clinical or laboratory tumor lysis syndrome (TLS) occurred, and only 9 patients discontinued combination treatment due to TEAEs. All patients responded to therapy, and nearly all achieved deep remission (undetectable disease in the blood). These deep responses occurred early and were maintained over time, including in patients with high-risk genetic features. The results support further research into this combination as a frontline therapy for CLL\/SLL.\r\n\r\n<em>The contents of the presentations above are designed for educational and scientific exchange purposes and are not promotional. They may contain information on investigational products or investigational uses of approved products. No conclusions regarding safety and\/or efficacy for such investigational products or uses may be made.<\/em>","table_heading":"","table":null,"faq_heading":"FREQUENTLY ASKED QUESTIONS","faq":null,"button_alt_link":"","no_post_image_preview":true,"download_file_reading":"https:\/\/beonemedaffairs.com\/us\/wp-content\/uploads\/sites\/11\/2025\/12\/ASH2025_phase-1-1b-bgb-11417-101-study-of-sonrotoclax-plus-zanubrutinib-in-tn-cll-sll_umrd.pdf","display_file_reading":null,"download_file_slidekit":null,"display_file_slidekit":null,"3qsdn":"","webcast":"","vimeo_url":"","videolange":null,"fliphtml_link":"","use_pdf_instead_of_fliphtml":false,"congress_resource_abstract_link":"","congress_resource_cta_label":"See abstract","congress_resource_cta_link":"https:\/\/meetings-api.hematology.org\/api\/abstract\/vmpreview\/293262","authors":[6577],"field_page_schema_override":[{"field_page_schema_override_type":"PresentationDigitalDocument","field_page_schema_override_data":"{\r\n  \"@type\": \"PresentationDigitalDocument\",\r\n  \"name\": \"Frontline treatment of sonrotoclax (BGB-11417) and zanubrutinib for chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) demonstrates high undetectable minimal residual disease (uMRD) rates with favorable tolerability: Updated data from BGB-11417-101, an ongoing phase 1\/1b study \u2013 BeOne Medical Affairs | US\", \r\n  \"description\": \"Check out the ASH 2025 poster on updated data from the phase 1\/1b BGB-11417-101 study of sonrotoclax + zanubrutinib in patients by Constantine S. Tam.\",  \r\n  \"image\": \"https:\/\/beonemedaffairs.com\/us\/wp-content\/uploads\/sites\/11\/2025\/10\/ASH2025_phase-1-1b-bgb-11417-101-study-of-sonrotoclax-plus-zanubrutinib-in-tn-cll-sll_umrd.jpeg\",\r\n  \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/phase-1-1b-bgb-11417-101-study-of-sonrotoclax-plus-zanubrutinib-in-tn-cll-sll_umrd\/\",  \r\n  \"associatedMedia\": {\r\n    \"@type\": \"MediaObject\",\r\n    \"contentUrl\": \"https:\/\/meetings-api.hematology.org\/api\/abstract\/vmpreview\/293262\",\r\n    \"encodingFormat\": \"application\/pdf\"\r\n  },\r\n  \"datePublished\": \"2025-12-07\",  \r\n  \"keywords\": [\"bgb-11417-101 clinical trials\", \"study of sonrotoclax zanubrutinib in cll\", \"early analysis of bgb-11417-101\", \"bgb-11417-101 in cll clinical research\"], \r\n  \"genre\": \"Poster\",   \r\n  \"author\": {\r\n    \"@type\": \"Person\",\r\n    \"name\": \"Constantine S. Tam, MBBS (Hons), MD\"\r\n  },\r\n  \"publisher\": {\r\n    \"@type\": \"Organization\",\r\n    \"name\": \"BeOne Medicines\",\r\n    \"url\": \"https:\/\/beonemedaffairs.com\/us\/\"\r\n  },\r\n  \"about\": {\r\n    \"@type\": \"MedicalStudy\",\r\n    \"name\": \"Frontline treatment of sonrotoclax (BGB-11417) and zanubrutinib for chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) demonstrates high undetectable minimal residual disease (uMRD) rates with favorable tolerability: Updated data from BGB-11417-101, an ongoing phase 1\/1b study\",  \r\n    \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/phase-1-1b-bgb-11417-101-study-of-sonrotoclax-plus-zanubrutinib-in-tn-cll-sll_umrd\/\"\r\n  }\r\n}"},{"field_page_schema_override_type":"MedicalWebPage","field_page_schema_override_data":"{\r\n  \"@type\": \"MedicalWebPage\",   \r\n  \"name\": \"Frontline treatment of sonrotoclax (BGB-11417) and zanubrutinib for chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) demonstrates high undetectable minimal residual disease (uMRD) rates with favorable tolerability: Updated data from BGB-11417-101, an ongoing phase 1\/1b study \u2013 BeOne Medical Affairs | US\",   \r\n  \"description\": \"Check out the ASH 2025 poster on updated data from the phase 1\/1b BGB-11417-101 study of sonrotoclax + zanubrutinib in patients by Constantine S. Tam.\",  \r\n  \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/phase-1-1b-bgb-11417-101-study-of-sonrotoclax-plus-zanubrutinib-in-tn-cll-sll_umrd\/\", \r\n  \"inLanguage\": \"en-US\",\r\n  \"@logo\": {\r\n    \"@type\": \"ImageObject\",\r\n    \"url\": \"https:\/\/beonemedaffairs.com\/us\/wp-content\/uploads\/sites\/11\/2025\/03\/BGI2404-BeOne-Primary-Logo-RGB-M04-V01-2.svg\"\r\n  }\r\n}"}]},"_links":{"self":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/congress-resource\/7588","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/congress-resource"}],"about":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/types\/congress-resource"}],"acf:post":[{"embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/authors\/6577"},{"embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/congress\/6819"}],"acf:term":[{"embeddable":true,"taxonomy":"content_type","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/content_type\/246"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/877"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/876"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/673"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/628"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/614"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/630"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/542"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/537"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/827"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/595"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/594"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/781"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/760"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/704"},{"embeddable":true,"taxonomy":"congress_resource_type","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/congress_resource_type\/245"}],"wp:attachment":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/media?parent=7588"}],"wp:term":[{"taxonomy":"post-tag","embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag?post=7588"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}